TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA therapeutics for high-risk and advanced cancers, announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately. Fitzgerald, who also served as a director, will continue to provide transition services to ensure a smooth handover. The company has appointed John Tattory as interim CFO, also effective immediately.
Tattory brings over 25 years of financial and operational management experience across the pharmaceutical, medical device, and biotechnology sectors. His career includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, he serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies. His extensive background in financial leadership and life sciences is expected to be instrumental as TransCode continues to advance its therapeutic pipeline.
The leadership change comes at a critical time for TransCode, which is focused on developing innovative treatments for metastatic cancers. The company's lead candidate, TTX-MC138, targets tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. Additionally, TransCode has a portfolio of first-in-class candidates designed to mobilize the immune system against cancer cells. Tattory's expertise in financial strategy and operations will be vital in supporting the company's clinical development and potential commercialization efforts.
Investors and stakeholders can view the full press release at https://nnw.fm/8G3ik. For ongoing news and updates about TransCode Therapeutics, the company's newsroom is available at https://nnw.fm/RNAZ.
The appointment of an interim CFO with Tattory's depth of experience in life sciences financial management signals TransCode's commitment to maintaining strong financial stewardship as it navigates the complex landscape of clinical trials and regulatory processes. His background in both large pharmaceutical firms and smaller biotech companies provides a versatile skill set that aligns with TransCode's stage of development. As the company continues to pioneer RNA-based therapies, effective financial leadership will be crucial for securing funding, managing resources, and driving long-term growth. This transition underscores TransCode's strategic focus on bringing novel cancer treatments to patients while optimizing its operational and financial performance.
